Expert Interview
Discussing the potential of Mavacamten, currently under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Ticker(s): BMYInstitution: Be Well Primary Health Care Center
- Board-certified osteopathic physician and is multi-board certified in Interventional Cardiology, Cardiovascular Disease, Endovascular Medicine, Nuclear Cardiology, and Internal Medicine.
- Clinical expertise includes transradial cardiac catheterization, Peripheral vascular endovascular intervention, Acute myocardial infarction and NSTEMI intervention, and Structural heart intervention.
- Manages treatment for 20 patients with HCM, 7000 patients with cardiovascular disease.
- Is somewhat familiar with Mavacamten and the findings from the VALOR-HCM and/or the EXPLORER-LTE clinical trial, and has prescribed Empagliflozin (Jardiance) to 400 patient
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
